Mohammed Elshahat

Dr. Mohammed Elshahat

Medical intern
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2022 in Clinical Cardiology
Verified
Journal Article
Open access
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
MAMohamed T. Abuelazm
Mohamed T. Abuelazm
Sarya SwedSarya Swed
Sarya Swed
Mohammed ElshahatMohammed Elshahat
Mohammed Elshahat
MAMostafa Atef
Mostafa Atef
AVAnnabelle S. Volgman
Annabelle S. Volgman
Radial artery spasm (RAS) is the most common cause of transradial access site crossover and is a common intra‐procedural complication. RAS incidence can lead to radial artery occlusion (RAO) postprocedure, preventing the radial artery as a future access site. We evaluated the efficacy of nitroglycerin preventing RAS and RAO during transradial catheterization discussing the different routes of administration, including topical, subcutaneous, and intra‐arterial. A systematic review and meta‐analysis included all relevant articles until April 23, 2022. We searched six databases Google Scholar, Web of Science, SCOPUS, EMBASE, PubMed (MEDLINE), and CENTRAL. We registered our review protocol in PROSPERO with ID: CRD42022330356. We included 11 trials with 5814 patients. Compared to placebo, the pooled analysis favored subcutaneous nitroglycerin in preventing RAS (risk ratio [RR]: 0.57 with 95% confidence interval [CI] [0.43–0.77], p = .0003) and RAO (RR: 0.39 with 95% CI [0.16–0.98], p = .05). In contrast to the intra‐arterial nitroglycerin that showed nonstatistically significant results in preventing RAS and RAO (RR: 0.8 with 95% CI [0.63–1.02], p = .07)‐ (RR: 0.78 with 95% CI [0.6–1.01], p = .06)), respectively. Also, topical nitroglycerin did not prevent RAS (RR: 0.73 with 95% CI [0.42–1.24], p = .24). Compared with placebo, subcutaneous nitroglycerin during transradial catheterization reduced the incidence of RAS and RAO. Meanwhile, Intra‐arterial and topical nitroglycerin did not show statistically significant outcomes. Subcutaneous nitroglycerin may be a practical and cost‐effective technique to facilitate transradial catheterization; however, more RCTs are needed to evaluate the subcutaneous versus intra‐arterial nitroglycerin administration.

24 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
SMShoaib Muhammad
Shoaib Muhammad
Mohammed ElshahatMohammed Elshahat
Mohammed Elshahat
FLFatma Labieb
Fatma Labieb
MAMostafa Atef Amin
Mostafa Atef Amin
James Robert BrasicJames Robert Brasic
James Robert Brasic
Irritable bowel syndrome (IBS), a gastrointestinal disorder affecting 7–12% of the population, is characterized by abdominal pain, bloating, and alternating bowel patterns. Data on risk and protective influences have yielded conflicting evidence on the effects of alternative interventions, such as vitamin D. This review focuses on the effects of vitamin D on IBS. A systematic review and meta-analysis considered all articles published until 4 April 2022. The search for randomized controlled trials assessing vitamin D efficacy in IBS with outcomes, primary (Irritable Bowel Severity Scoring System (IBS-SSS)) and secondary (IBS quality of life (IBS-QoL) and serum level of calcifediol (25(OH)D)), was performed on six databases, Google Scholar, Web of Science, SCOPUS, EMBASE, PubMed (MEDLINE), and Cochrane Central Register of Controlled Trials. We included six trials with 616 patients. The pooled analysis found no difference between vitamin D and placebo in improving IBS-SSS (MD: −45.82 with 95% CI [−93.62, 1.98], p = 0.06). However, the pooled analysis favored vitamin D over placebo in improving the IBS-Qol (MD: 6.19 with 95% CI [0.35, 12.03], p = 0.04) and serum 25(OH)D (MD: 25.2 with 95% CI [18.41, 31.98], p = 0.00001). Therefore, further clinical trials are required to reach clinically applicable and generalizable findings.

26 January 2022 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
HBHelmy Badr
Helmy Badr
Mohammed ElshahatMohammed Elshahat
Mohammed Elshahat
MAMohamed Ashraf
Mohamed Ashraf
SASherief Abd‐Elsalam
Sherief Abd‐Elsalam
Objective: Lymphatic filariasis is a serious public health issue. Recent studies showed that a single dosage of triple therapy (Ivermectin, Diethylcarbamazepine, and Albendazole) is more effective than dual therapy (Ivermectin plus Albendazole or Diethylcarbamazepine plus Albendazole) for clearing microfilaria from the blood. We aimed to evaluate the efficacy and safety of triple therapy versus dual therapy in patients infected with microfilaria and communities endemic to lymphatic filariasis.Methods: For this systematic review and meta‐analysis, we searched MEDLINE, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials, and Web of Science until 24th June 2021. We included randomized control trials that compared triple with dual therapy given to patients with lymphatic filariasis or endemic communities. This study was registered with PROSPERO (CRD42021266724).Results: We included eight articles after the screening process. Triple therapy caused more clearance of microfilaria in the blood (RR: 1.52; 95% CI: 1.15, 2.02; p = 0.003), while dual therapy caused more clearance of the circulating filariae antigen in the blood (RR: 0.76; 95% CI: 0.65, 0.88; p = 0.0003), both 12 months after drug administration. The triple therapy had a similar adverse effect compared with the dual therapy group.Conclusion: Based on the greater efficacy in the clearance of microfilaria and the safety of triple therapy, it constitutes a better strategy for the eradication programs of lymphatic filariasis in endemic regions. However, further studies are needed to confirm our results.

16 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
BKBasant E. Katamesh
Basant E. Katamesh
Mohammed ElshahatMohammed Elshahat
Mohammed Elshahat
LKL V Simhachalam Kutikuppala
L V Simhachalam Kutikuppala
TPTimir K. Paul
Timir K. Paul
Transcatheter aortic valve replacement (TAVR) is now considered the mainstay of aortic stenosis management; however, the optimal antithrombotic therapy in patent without indications for an oral anticoagulant (OAC) is yet to be identified. Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy and safety of direct oral anticoagulant (DOAC) treatment versus the standard of care in patients without indications of OACs after TAVR. We synthesized randomized controlled trials (RCTs) from Web of Science, SCOPUS, EMBASE, PubMed, and Cochrane until 18 August 2022. We used the risk ratio (RR) for dichotomous outcomes with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022357027. Three RCTs with 2922 patients were identified. DOACs were significantly associated with higher incidence of all-cause mortality (RR: 1.68 with 95% CI [1.22, 2.30], p = 0.001), mortality due to non-cardiovascular causes (RR: 2.34 with 95% CI [1.36, 4.02], p = 0.002), and the composite outcome of death, myocardial infarction, or stroke (RR: 1.41 with 95% CI [1.13, 1.76], p = 0.002). However, DOACs were associated with decreased incidence of reduced leaflet motion (RLM) (RR: 0.19 with 95% CI [0.09, 0.41], p = 0.0001) and hypoattenuated leaflet thickening (HALT) (RR: 0.50 with 95% CI [0.36, 0.70], p = 0.0001). DOACs were effective to reduce RLM and HALT; however, the clinical effect of this is still controversial. DOACs were associated with worse efficacy and safety outcomes, including all-cause mortality. Further RCTs investigating the optimal antithrombotic regimen after TAVR.

20 April 2022 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
Mohammed ElshahatMohammed Elshahat
Mohammed Elshahat
Manar Ahmed KamalManar Ahmed Kamal
Manar Ahmed Kamal
Mohamed Tarek AbuelazmMohamed Tarek Abuelazm
Mohamed Tarek Abuelazm
AYAmman Yousaf
Amman Yousaf
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
Endoscopic retrograde cholangiopancreatography (ERCP) identifies and treats pancreatic and biliary diseases. We conducted a systematic review and meta-analysis examining relevant papers in five databases to examine the frequency of hypoxia throughout the surgery and the lowest oxygen saturation level in patients under sedation. Our meta-analysis included three randomized controlled trials with 390 participants, 196 in the high-flow oxygen (HFNC) group and 194 in the low-flow oxygen (LFNC) group. Their ages ranged from 65.3 to 79 years. The pooled effect estimate showed that HFNC decreased the incidence of hypoxia during the procedure when compared to LFNC (odds ratio −0.84; 95% confidence interval [CI] −1.65, −0.02; P = 0.04), and the mean of lowest oxygen saturation in patients during sedation was significantly lower in LFNC compared to HFNC (mean difference 2.34; 95% CI 1.35, 3.32; P = 0.001). The pooled effect estimate showed that the HFNC group had a lower incidence rate of jaw thrusting adverse events during anesthesia than the LFNC group (risk difference −0.12; 95% CI −0.21, −0.04; P = 0.001). In summary, HFNC systems reduced the incidence of hypoxia for patients undergoing ERCP and had a higher mean lowest oxygen saturation during sedation.

7 October 2022 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MSMostafa Shahien
Mostafa Shahien
AEAbdelrahman Elaraby
Abdelrahman Elaraby
Mohammed ElshahatMohammed Elshahat
Mohammed Elshahat
EAEslam Abdelazim
Eslam Abdelazim
Basel AbdelazeemBasel Abdelazeem
Basel Abdelazeem
Ahmed NegidaAhmed Negida
Ahmed Negida